Q-omics provides the consensus-scored MIR3186 profile across patient tissues and cancer cell-line models. MIR3186 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR3186 is differentially expressed in 9, with the highest sampling consensus in CHOL. Additionally, MIR3186 RNA expression shows 16,302 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, CHOL, and TGCT as cancer lineages where MIR3186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3186 survival associations across molecular data types. MIR3186 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3186 RNA expression–survival associations across cancer types. High MIR3186 expression shows unfavorable associations in ACC, UVM, THCA, STAD and CHOL, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR3186 RNA expression.
This table summarizes MIR3186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3186 shows lower tumor expression in KIRP, THCA, KICH and BRCA and higher tumor expression in CHOL and PAAD. The CHOL box plot shows higher MIR3186 RNA expression in tumor versus normal tissue (log2 FC = +1.837, t-test p < 0.001).
This table shows molecular features associated with MIR3186 in patient tissues and cancer cell lines. In patient samples, MIR3186 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
